Arcus Biosciences, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Arcus Biosciences, Inc. (RCUS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $33.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $33.00M, a 312.50% increase year-over-year.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $7.00M, a 12.50% decline year-over-year.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $11.00M, a 52.17% decline year-over-year.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $6.00M, a 14.29% decline year-over-year.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $33.00M, a 35.29% decline from fiscal 2024.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $51.00M, a 37.84% increase from fiscal 2023.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $37.00M, a 2.63% decline from fiscal 2022.
- Arcus Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $38.00M, a 90.08% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.00M 10-Q · filed 2026-08-05 | $40.00M 10-Q · filed 2026-08-05 | $51.00M derived: sum of 3 quarters · filed 2026-08-05 | $57.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-05 | $18.00M derived: sum of 2 quarters · filed 2026-05-05 | $24.00M derived: sum of 3 quarters · filed 2026-05-05 | $32.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $17.00M derived: sum of 2 quarters · filed 2026-02-25 | $25.00M derived: sum of 3 quarters · filed 2026-08-05 | $33.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $6.00M 10-Q · filed 2025-10-28 | $14.00M derived: sum of 2 quarters · filed 2026-08-05 | $22.00M 10-Q · filed 2025-10-28 | $45.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $8.00M 10-Q · filed 2026-08-05 | $16.00M 10-Q · filed 2026-08-05 | $39.00M derived: sum of 3 quarters · filed 2026-08-05 | $46.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $8.00M 10-Q · filed 2026-05-05 | $31.00M derived: sum of 2 quarters · filed 2026-05-05 | $38.00M derived: sum of 3 quarters · filed 2026-05-05 | $49.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $30.00M derived: sum of 2 quarters · filed 2026-02-25 | $41.00M derived: sum of 3 quarters · filed 2026-02-25 | $51.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $7.00M 10-Q · filed 2025-10-28 | $48.00M 10-Q · filed 2024-11-06 | $18.00M derived: sum of 2 quarters · filed 2025-10-28 | $28.00M 10-Q · filed 2025-10-28 | $232.00M 10-Q · filed 2024-11-06 | -$21.00M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | $11.00M 10-Q · filed 2025-08-06 | $39.00M 10-Q · filed 2024-08-08 | $21.00M 10-Q · filed 2025-08-06 | $184.00M 10-Q · filed 2024-08-08 | -$28.00M derived: sum of 3 quarters · filed 2026-02-25 | $4.00M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $10.00M 10-Q · filed 2025-05-06 | $145.00M 10-Q · filed 2024-05-08 | -$39.00M derived: sum of 2 quarters · filed 2026-02-25 | -$7.00M derived: sum of 3 quarters · filed 2026-02-25 | $22.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | -$49.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$17.00M derived: sum of 2 quarters · filed 2026-02-25 | $12.00M derived: sum of 3 quarters · filed 2026-02-25 | $37.00M 10-K · filed 2026-02-25 | $117.00M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $32.00M 10-Q · filed 2024-11-06 | $61.00M derived: sum of 2 quarters · filed 2024-11-06 | $86.00M 10-Q · filed 2024-11-06 | $46.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $29.00M 10-Q · filed 2024-08-08 | $54.00M 10-Q · filed 2024-08-08 | $14.00M derived: sum of 3 quarters · filed 2025-02-25 | $47.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $25.00M 10-Q · filed 2024-05-08 | -$15.00M derived: sum of 2 quarters · filed 2025-02-25 | $18.00M derived: sum of 3 quarters · filed 2025-02-25 | $45.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$7.00M derived: sum of 2 quarters · filed 2025-02-25 | $20.00M derived: sum of 3 quarters · filed 2025-02-25 | $38.00M 10-K · filed 2025-02-25 | $112.00M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $33.00M 10-Q · filed 2023-11-07 | $33.58M 10-Q · filed 2022-11-02 | $60.00M derived: sum of 2 quarters · filed 2023-11-07 | $78.00M 10-Q · filed 2023-11-07 | $78.34M 10-Q · filed 2022-11-02 | $432.62M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $27.00M 10-Q · filed 2023-08-07 | $26.76M 10-Q · filed 2022-08-03 | $45.00M 10-Q · filed 2023-08-07 | $44.76M 10-Q · filed 2022-08-03 | $399.62M derived: sum of 3 quarters · filed 2024-02-21 | $409.08M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $18.00M 10-Q · filed 2023-05-09 | $18.00M 10-Q · filed 2022-05-09 | $372.62M derived: sum of 2 quarters · filed 2024-02-21 | $382.08M derived: sum of 3 quarters · filed 2024-02-21 | $391.54M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $354.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $364.08M derived: sum of 2 quarters · filed 2024-02-21 | $373.54M derived: sum of 3 quarters · filed 2024-02-21 | $383.00M 10-K · filed 2024-02-21 | $382.88M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $9.46M 10-Q · filed 2022-11-02 | $18.92M derived: sum of 2 quarters · filed 2022-11-02 | $28.38M 10-Q · filed 2022-11-02 | $38.35M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $9.46M 10-Q · filed 2022-08-03 | $18.92M 10-Q · filed 2022-08-03 | $28.89M derived: sum of 3 quarters · filed 2023-02-28 | $93.42M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $9.46M 10-Q · filed 2022-05-09 | $19.43M derived: sum of 2 quarters · filed 2023-02-28 | $83.96M derived: sum of 3 quarters · filed 2023-02-28 | $85.71M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $9.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $74.50M derived: sum of 2 quarters · filed 2023-02-28 | $76.25M derived: sum of 3 quarters · filed 2023-02-28 | $78.00M 10-K · filed 2023-02-28 | $77.52M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $64.53M 10-Q · filed 2021-11-08 | $66.28M derived: sum of 2 quarters · filed 2021-11-08 | $68.03M 10-Q · filed 2021-11-08 | $77.78M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | $1.75M 10-Q · filed 2021-08-05 | $3.50M 10-Q · filed 2021-08-05 | $13.25M derived: sum of 3 quarters · filed 2022-02-23 | $15.00M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | $1.75M 10-Q · filed 2021-05-05 | $11.50M derived: sum of 2 quarters · filed 2022-02-23 | $13.25M derived: sum of 3 quarters · filed 2022-02-23 | $15.00M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $11.50M derived: sum of 2 quarters · filed 2022-02-23 | $13.25M derived: sum of 3 quarters · filed 2022-02-23 | $15.00M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $1.75M 10-Q · filed 2020-11-05 | $3.50M derived: sum of 2 quarters · filed 2020-11-05 | $5.25M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $1.75M 10-Q · filed 2020-08-06 | $3.50M 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $1.75M 10-Q · filed 2020-05-05 | |||||||
| 2018-12-31 | $8.35M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |